Purchase this article with an account.
R.E. Evans, F.A. Bucci, Jr, L.M. Amico; Efficacy of Ketorolac 0.5% versus Ketorolac 0.4% Following Cataract Surgery . Invest. Ophthalmol. Vis. Sci. 2005;46(13):790.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To compare the efficacy of ketorolac 0.5% (AcularTM, Allergan Inc.) and ketorolac 0.4% (AcularLS®, Allergan Inc.) in controlling mild to moderate inflammation, as measured by aqueous flare, following cataract surgery. Methods:Forty eight patients were randomized to 1 of 2 ophthalmic formulations of ketorolac (Acular®, n = 23; or Acular LSTM, n = 25), which were dosed QID for 2 days prior to surgery then Q 10 minutes x 4 doses beginning 1 hour prior to surgery, and then QID for 2 weeks after surgery. A KOWA flare meter (Keeler Ltd., Berkshire, UK) was used to measure aqueous flare at 1 day, 1 week, and 2 weeks post phaco. Results:Flare results (expressed in p/msec) are as follows for the 1 day, 1 week, and 2 week postop visits, respectively: Acular®: 37.4, 22.1, 18.4; Acular LSTM: 40.0, 20.2, 16.9. No statistically significant differences were found in postoperative flare between the two therapeutic regimens at any of the 3 post op visits. Conclusions: Acular® and Acular LSTM were equally effective in controlling inflammation after cataract surgery as measured by aqueous flare.
This PDF is available to Subscribers Only